Danaher (DHR) Q4 and Annual 2025 Earnings
Danaher reported Q4 2025 revenue of $6.8B (+4.6% YoY), beat analyst consensus of $6.8B by $27.3M. Diluted EPS came in at $2.23 (+4.2% YoY), beat the $2.16 consensus by $0.07. Danaher reports across 3 business segments, led by Diagnostics, Biotechnology, and Life Sciences.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Danaher's Q4 2025 earnings report.
Danaher (DHR) reported Q4 2025 earnings on January 28, 2026 before market open.
Danaher reported revenue of $6.8B and diluted EPS of $2.23 for Q4 2025.
Revenue beat the consensus estimate of $6.8B by $27.3M. EPS beat the consensus estimate of $2.16 by $0.07.
Compared to the same quarter a year prior, revenue grew 4.6% from $6.5B a year earlier and diluted EPS grew 4.2% from $2.14.
Danaher reports across 3 business segments, led by Diagnostics, Biotechnology, and Life Sciences. Segment-level financials are available on the company's metrics pages.
You can read the 10-K periodic report (0000313616-26-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.